Arvinas Inc. (ARVN)
Company Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
The company has collaborations with Pfizer Inc., Genentech, Inc., F.
Hoffman-La Roche Ltd., and Bayer AG.
Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Country | United States |
IPO Date | Sep 27, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 430 |
CEO | Dr. John G. Houston Ph.D. |
Contact Details
Address: 5 Science Park New Haven, Connecticut United States | |
Website | https://www.arvinas.com |
Stock Details
Ticker Symbol | ARVN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001655759 |
CUSIP Number | 04335A105 |
ISIN Number | US04335A1051 |
Employer ID | 47-2566120 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. John G. Houston Ph.D. | Chairperson, Chief Executive Officer & President |
Andrew R. Saik | Chief Financial Officer & Treasurer |
Angela M. Cacace Ph.D. | Chief Scientific Officer |
David K. Loomis M.B.A. | Vice President & Chief Accounting Officer |
Dr. Ian Taylor Ph.D. | President of Research & Development and Chairman of Scientific Advisory Board |
Dr. Randy Teel Ph.D. | Chief Business Officer |
Jared M. Freedberg J.D. | General Counsel & Corporate Secretary |
Lisa Sinclair | Senior Vice President of Corporate Operations |
Paul McInulty | Senior Vice President of Regulatory Affairs |
Steve Weiss | Senior Vice President & Chief Human Resources Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 19, 2025 | 4 | Filing |
Mar 11, 2025 | 8-K | Current Report |
Feb 25, 2025 | 4 | Filing |
Feb 25, 2025 | 4 | Filing |
Feb 25, 2025 | 4 | Filing |
Feb 25, 2025 | 4 | Filing |
Feb 18, 2025 | 4 | Filing |
Feb 18, 2025 | 4 | Filing |
Feb 18, 2025 | 4 | Filing |
Feb 18, 2025 | 4 | Filing |